Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;310(1):11-28.
doi: 10.1007/s00403-017-1789-1. Epub 2017 Oct 25.

IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review

Affiliations

IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review

Ariadne Hadjikyriacou Saniklidou et al. Arch Dermatol Res. 2018 Jan.

Abstract

Bullous pemphigoid (BP) is the most common autoimmune skin disease of blistering character. The underlying pathophysiological mechanism involves an immune attack, usually by IgG class autoantibodies, on the autoantigen BP 180/BPAg2, which is a type XVII collagen (COL17) protein acting as the adhesion molecule between the epidermis and the basement membrane of the dermis. About 40 years ago, following consistent findings of elevated total serum IgE levels in BP patients, it was hypothesized that IgE may be involved in the pathophysiology of BP. Our objective was to determine whether there is strong evidence for an association between IgE class autoantibodies and the clinical severity or phenotype of BP. Three databases were searched for relevant studies and appropriate exclusion and inclusion criteria were applied. Data was extracted and assessed in relation to the study questions concerning the clinical significance of IgE autoantibodies in BP. Nine studies found that anti-BP180 autoantibodies of IgE class are associated with increased severity of BP, whereas two studies did not find such an association. The number of studies which found an association between higher IgE autoantibody levels and the erythematous urticarial phenotype of BP (5) was equal in number to the studies which found no such association (5). In conclusion, higher serum IgE autoantibody levels are associated with more severe clinical manifestations of BP. There is insufficient evidence to support higher IgE autoantibody levels being associated with specific clinical phenotypes of BP.

Keywords: Autoantibodies; BP; Bullous pemphigoid; Clinical manifestations; Clinical phenotype; Disease activity; Disease course; Disease severity; IgE; Immunoglobulin E.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Fig. 1
Fig. 1
PRISMA 2009 flow diagram used to illustrate the study selection process for the systematic review. This shows the process of searching for records, removing duplicates, screening titles and abstracts, assessing full texts for eligibility and selecting which studies would be used in the analysis
Fig. 2
Fig. 2
The number of studies published each year between 1974 and 2016 relevant to the relationship between IgE autoantibodies and BP

References

    1. Altrichter S, Kriehuber E, Moser J, Valenta R, Kopp T, Stingl G. Serum IgE autoantibodies target keratinocytes in patients with atopic dermatitis. J Invest Dermatol. 2008;128:2232–2239. doi: 10.1038/jid.2008.80. - DOI - PubMed
    1. Amber KT. Is anti-BP180 IgE associated with clinical phenotype? A reply to ‘Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid’. Arch Dermatol Res. 2016;308:65–66. doi: 10.1007/s00403-015-1609-4. - DOI - PubMed
    1. Arbesman CE, Wypych JI, Reisman RE, Beutner EH. IgE levels in sera of patients with pemphigus or bullous pemphigoid. Arch Dermatol. 1974;110:378–381. doi: 10.1001/archderm.1974.01630090016003. - DOI - PubMed
    1. Asbrink E, Hovmark A. Serum IgE levels in patients with bullous pemphigoid and its correlation to the activity of the disease and anti-basement membrane zone antibodies. Acta Derm Venereol. 1984;64:243–246. - PubMed
    1. Baba T, Sonozaki H, Seki K, Uchiyama M, Ikesawa Y, Toriisu M. An eosinophil chemotactic factor present in blister fluids of bullous pemphigoid patients. J Immunol. 1976;116:112–116. - PubMed
Related articles recently published in Archives of Dermatological Research (selected by the journal’s editorial staff)
    1. Kalinska-Bienias A, Lukowska-Smorawska K, Jagielski P, Kowalewski C, Wozniak K. Mortality in bullous pemphigoid and prognostic factors in 1st and 3rd year of follow-up in specialized centre in Poland. Arch Dermatol Res. 2017 - PubMed
    1. Keller JJ, Kittridge AL, Debanne SM, Korman NJ. Evaluation of ELISA testing for BP180 and BP230 as a diagnostic modality for bullous pemphigoid: a clinical experience. Arch Dermatol Res. 2016;308:269–272. doi: 10.1007/s00403-016-1631-1. - DOI - PubMed
    1. Liu YD, Wang YH, Ye YC, Zhao WL, Li L. Prognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis. Arch Dermatol Res. 2017;309:335–347. doi: 10.1007/s00403-017-1736-1. - DOI - PMC - PubMed
    1. Mersmann M, Dworschak J, Ebermann K, Komorowski L, Schlumberger W, Stocker W, Zillikens D, Probst C, Schmidt E. Immunoadsorber for specific apheresis of autoantibodies in the treatment of bullous pemphigoid. Arch Dermatol Res. 2016;308:31–38. doi: 10.1007/s00403-015-1606-7. - DOI - PubMed
    1. Thorslund K, Seifert O, Nilzen K, Gronhagen C. Incidence of bullous pemphigoid in Sweden 2005–2012: a nationwide population-based cohort study of 3761 patients. Arch Dermatol Res. 2017 - PMC - PubMed

Publication types